Furthermore, the T790M ratio between the 1st- and 2nd-G EGFR-TKIs was almost similar in patients with EGFR-TKI-refractory NSCLC who showed response to osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.